Stockholders' Equity (Details Narrative) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Sep. 30, 2019 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Mar. 31, 2020 |
|
| Common stock, forfeited | 7,872 | |||
| Preferred stock, shares issued | ||||
| Preferred stock, shares outstanding | ||||
| Pledge Agreement with PoC [Member] | ||||
| Clinical trial funding commitment | $ 1,800,000 | |||
| Reduced clinical trial funding commitment | $ 900,000 | |||
| Common stock, forfeited | 56,640 | |||
| Warrants, forfeited | 56,640 | |||
| X | ||||||||||
- Definition Clinical Trial Funding commitment in reduction for subscription receivable. No definition available.
|
| X | ||||||||||
- Definition Reduced clinical trial funding commitment. No definition available.
|
| X | ||||||||||
- Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|